EUVIMEDOpdag EUVIMED
Crossref

Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia

Tianli Liu, Xiaoling Cheng, Yupeng Wang, Wenli Hao, Hangyu Wang, Ke Zhang iD, Jinhui Wang iD

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70127 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Tianli Liu and 6 co-authors. Institution: Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, College of Pharmacy, Shihezi University, Shihezi, China. Major MEDLINE topics: Antineoplastic Agents, DNA-Directed RNA Polymerases, Drug Design, Enzyme Inhibitors. Cited 2 times so far (Crossref); 21 references. Funded by: Regional Joint Fund of National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The metabolic dependence of acute myeloid leukemia (AML) cells on mitochondrial oxidative phosphorylation (OXPHOS) has become a cutting‐edge area in cancer energy metabolism research, playing a pivotal role in cell survival and drug resistance. Consequently, targeted inhibition of human mitochondrial RNA polymerase (POLRMT) to block mitochondrial gene expression emerges as a novel potential strategy for treating AML through OXPHOS modulation. In this study, based on the previously reported crystal structure of the POLRMT inhibitor IMT1B, we employed a scaffold hopping strategy to design and synthesize a series of derivatives featuring additional hydrophobic occupying groups. A new potent POLRMT inhibitor ( 10a ) was discovered, which displayed potent antiproliferative activity and could disrupt mitochondrial function and induce apoptosis in MOLM‐13 cells. Together, these results demonstrate that 10a is a new POLRMT inhibitor, which may provide a candidate lead for AML treatment.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsDNA-Directed RNA PolymerasesDrug DesignEnzyme InhibitorsLeukemia, Myeloid, AcuteHumansApoptosisCell Line, TumorCell ProliferationMitochondriaMolecular Docking SimulationOxidative PhosphorylationStructure-Activity Relationship

Author keywords

AMLOXPHOSPOLRMT inhibitor

Substances

Antineoplastic AgentsDNA-Directed RNA PolymerasesEnzyme InhibitorsPOLRMT protein, human

Authors and institutions

  • Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, College of Pharmacy, Shihezi University, Shihezi, China.

ORCID profiles: Ke Zhang, Jinhui Wang

Funding

  • Regional Joint Fund of National Natural Science Foundation of China

Cite

APA

Liu, T., Cheng, X., Wang, Y., Hao, W., Wang, H., Zhang, K., & Wang, J. (2025). Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70127

Vancouver

Liu T, Cheng X, Wang Y, Hao W, Wang H, Zhang K, et al. Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70127

BibTeX
@article{Liu2025,
  author = {Liu, Tianli and Cheng, Xiaoling and Wang, Yupeng and Hao, Wenli and Wang, Hangyu and Zhang, Ke and Wang, Jinhui},
  title = {Design, Synthesis and Biological Evaluation of POLRMT Inhibitors for the Treatment of Acute Myeloid Leukemia},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70127}
}
Start for free →